Check out our new Prevention line of spa and salon disinfectants. Available  now.
Click here to learn about our new Rejuvenate Special Edition Wipes

To Whom it May Concern,

In cases of emerging viral pathogens such as Monkeypox Virus, when there is no test that can be conducted to validate the efficacy of a disinfectant, the US Environmental Protection Agency utilizes their Emerging Viral Pathogens Policy to determine the expected efficacy of a disinfectant against an emerging virus. In the case of an enveloped virus such as Monkeypox Virus, the following criteria are used to determine efficacy of a disinfectant upon enactment of the Emerging Viral Pathogens Policy:

  1. The product must be a hospital or broad-spectrum disinfectant product registered with the EPA.
  2. The product must have acceptable efficacy data previously submitted to and reviewed by the

    Agency against at least one non-enveloped virus, which is considered to be more resistant to disinfectants compared to enveloped viruses such as Monkeypox Virus.

The Rejuvenate line of disinfectants (including Rejuvenate Concentrate, Ready-to-Use liquid and Wipes) fulfill these criteria and therefore can be used against Monkeypox Virus on hard, non-porous surfaces as part of a facility’s infection prevention and control protocols. Rejuvenate Concentrate (EPA Reg. No. 74559-4) should be applied at a 1:16 dilution for a contact time of five minutes. Rejuvenate Ready-to-Use liquid (EPA Reg. No. 74559-1) and Wipes (EPA Reg. No. 74559-3) should be applied with a one-minute contact time. To learn more about this ongoing situation as it unfolds, please refer to the CDC’s information page at the following link:

Should you require any further information, please do not hesitate to contact us at 1-800-387-7578. Best regards,

Junette D. Tabadero

Director, Regulatory Affairs Virox Technologies Inc.

Download PDF